December 8, 2025BloodOpen Access

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

View Full Paper

Ask AI

Bookmark

No thrombotic events occurred during immune tolerance induction with emicizumab, confirming its safety in treatment.
Limited adverse events reported, with one Grade 1 event deemed emicizumab-related, which resolved quickly.
Multicenter study enrolled 12 male participants, providing valuable safety data and insights into treatment outcomes with emicizumab.
Findings support the combined use of emicizumab during immune tolerance induction therapy in managing factor VIII inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Interim analysis reveals safety profile of emicizumab during immune tolerance induction in hemophilia A, highlighting adverse events and thrombotic events.

Cite This Study

Nogami et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6f5 https://doi.org/10.1182/blood-2025-303

View Full Paper

Ask AI

Bookmark

Implication

Interim analysis reveals safety profile of emicizumab during immune tolerance induction in hemophilia A, highlighting adverse events and thrombotic events.

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Key Points

Discussion

Implication

Cite This Study

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading